Lixte Biotechnology (NASDAQ:LIXT) Releases Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) released its quarterly earnings data on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, Zacks reports.

Lixte Biotechnology Trading Up 0.1 %

Shares of Lixte Biotechnology stock opened at $1.30 on Tuesday. The firm’s 50-day moving average price is $1.79 and its two-hundred day moving average price is $1.88. Lixte Biotechnology has a 1-year low of $1.02 and a 1-year high of $4.40. The stock has a market capitalization of $2.93 million, a price-to-earnings ratio of -0.75 and a beta of 0.19.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.